- One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV events in elderly NVAF patients1 - The Global ETNA-AF programme is currently the largest and most comprehensive repository of routine clinical ...
- Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation (AF) patients following a successful percutaneous coronary ...
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction -36mg/dL, -21,4%) - Over 24-weeks, bempedoic acid was ...
Tokyo (ots/PRNewswire) - Daiichi Sankyo announces the initiation of Hokusai-VTE Cancer, a multinational study investigating edoxaban in venous thromboembolism (VTE) associated with cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the initiation of Hokusai-VTE Cancer, a multinational ...
Munich (ots/PRNewswire) - For distribution to the consumer and medical media across Europe (excluding the UK) - Findings From the Supporting Hypertension Awareness and Research Europe-wide (SHARE) Survey Suggest the Need to Implement a Consistent Strategy to Improve and Maintain Blood Pressure Control Physicians' ...
Munich (ots/PRNewswire) - Daiichi Sankyo announced today that it has begun enrolling patients in Europe into a large, multinational phase III trial of tivantinib (ARQ 197). Tivantinib is an investigational small molecule inhibitor of the c-MET receptor tyrosine kinase in final phase of clinical development for the ...
Tokyo and Woburn, Massachusetts (ots/PRNewswire) - Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. today announced that the first patient has been enrolled in the phase III trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, ...
Munich (ots/PRNewswire) - Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This new drug combines the three widely prescribed blood pressure ...
Woburn, Massachusetts (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, ...
Oslo, June 21, 2010 (ots/PRNewswire) - Data announced for the first time at ESH suggest that patients with hypertension are at increased cardiovascular risk due to clinician inertia, because physicians are failing to treat targets set by accepted ESH-ESC (European Society of Hypertension and European Society of Cardiology) guidelines for the management of arterial hypertension and do not act soon enough to reduce blood ...
Tokyo, April 6, 2010 (ots/PRNewswire) - Daiichi Sankyo Company, Limited announced today that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan seeking approval of the anticoagulant, edoxaban, for the prevention of venous thromboembolism (VTE) after major orthopedic surgery. Edoxaban, being developed solely by Daiichi ...
Nuremberg, Germany, February 26, 2010 (ots/PRNewswire) - Edoxaban, a direct oral factor Xa inhibitor, is now being investigated in a second large-scale pivotal phase III trial, HOKUSAI (pronounced hoek-sigh) VTE. This phase III trial is evaluating the safety and efficacy of edoxaban in the treatment and ...